NCT03666923View on ClinicalTrials.gov

A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 17, 2018

Primary Completion Date

November 20, 2019

Study Completion Date

November 20, 2019

Conditions
Diabetes MellitusDiabetic RetinopathyDiabetic Macular Edema
Interventions
DRUG

THR-687 dose level 1

single intravitreal injection of THR-687 dose level 1

DRUG

THR-687 dose level 2

single intravitreal injection of THR-687 dose level 2

DRUG

THR-687 dose level 3

single intravitreal injection of THR-687 dose level 3

Trial Locations (7)

29169

Palmetto Retinal Center, West Columbia

33880

Center for Retina and Macular Disease, Winter Haven

46290

Midwest Eye Institute, Indianapolis

78503

Valley Retina Institute, PA, McAllen

85053

Retina Consultants of Arizona, Phoenix

89502

Sierra Eye Associates, Reno

79606-1224

Retina Research Institute of Texas, Abilene

Sponsors

Lead Sponsor

ThromboGenics
All Listed Sponsors
lead

ThromboGenics

INDUSTRY

NCT03666923 - A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME) | Biotech Hunter | Biotech Hunter